Previous 10 | Next 10 |
2 Small Cap Stocks To Watch Before Friday Like it or not, small-cap stocks have emerged as a popular asset class to watch this quarter. More specifically, small-cap biotech stocks are making big moves like never before. For this reason, it is gathering a lot of gamblers and crypto traders ...
Shares of Kezar Life Sciences (NASDAQ: KZR) are down by 11.7% as of 3:12 p.m. EDT on Tuesday, following the company's announcement of the pricing of a public offering of common stock. Kezar Life Sciences made this announcement after the market closed on Monday. Kezar Life Sciences -- whose ...
On June 4, small-cap biotech company Kezar Life Sciences (NASDAQ: KZR) announced updated phase 1/2 results from a clinical study evaluating KZR-616 for the treatment of patients with systemic lupus erythematosus (SLE) with and without lupus nephritis (LN). Investors seemed to like the d...
Kezar Life Sciences (NASDAQ: KZR ) has priced its public offering of 7,590,909 common shares at $5.50, and to certain investors in lieu thereof, pre-funded warrants to purchase 909,091 common shares at $5.499/warrant, for expected gross proceeds of $46.7M. More news on: Kezar L...
SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced th...
Kezar Life Sciences (NASDAQ: KZR ) to offer and sell shares of its common stock in an underwritten public offering. More news on: Kezar Life Sciences, Inc., Healthcare stocks news, , Read more ...
SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced th...
Aldeyra Therapeutics Goes Ahead with Reproxalap for Dry Eye Disease Aldeyra Therapeutics Inc. ( ALDX ) reported that it has struck a deal with the FDA for the use of Reactive Aldehyde Species or RASP for the treating dry eye disease. The agreement has been reached on the basis of meeting...
Gainers: Vislink Technologies (NASDAQ: VISL ) +174% . More news on: Vislink Technologies, Inc., Cinedigm Corp., Kezar Life Sciences, Inc., Stocks on the move, , Read more ...
Cinedigm (NASDAQ: CIDM ) +139% on partnering with Vewd for global OTT channel distribution. More news on: Cinedigm Corp., Kezar Life Sciences, Inc., LiveXLive Media, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...